

03C0
(Box seq)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

O I P E J C E S
JAN 21 2003
PATENT & TRADEMARK OFFICE

Applicants:	Benedict, et al.	Attorney Docket:	SBI-042-CIP
S/N:	09/748,038		
Filed:	12/22/00	Group:	N/A
For:	Method of Promoting Natural Bypass	Examiner:	N/A

Assistant Commissioner for Patents
Washington, D.C. 20231

**AMENDMENT AND RESPONSE TO OFFICE
ACTION DATED NOVEMBER 13, 2002**

This paper is filed in response to the *Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures* mailed November 13, 2002 and having a two month shortened statutory response period. It is believed that no additional fee is due. However, please charge and such additional fees to Sulzer Medica Deposit Account No. 09-0473.

Applicants submit herewith a Sequence Listing in paper and computer readable form, and request amendment of the application as follows:

IN THE SPECIFICATION

After page 30, which contains the Abstract, please delete the Sequence Listing previously submitted by response mailed July 2, 2002, and insert the attached Sequence Listing.

REMARKS

Applicants previously submitted a Sequence Listing for the present application on July 2, 2002. The present Office Action requests submission of a machine readable form of the Sequence Listing previously submitted. In preparing

this response, Applicants have noticed that one or more pages were apparently omitted from the previously submitted Sequence Listing, resulting in only eighteen sequences (and the identification of a nineteenth sequence) being provided to the Office. This omission was inadvertent, as indicated by the fact that 31 sequences are identified as being present at line <160> of the previous listing. Thus, Applicants made a good faith attempt to reply to the prior Office Action.

Further, in verifying the accuracy of each sequence in the listing, Applicants have discovered that the 12th amino acid residue in Sequence ID No. 13 was incorrectly designated as an arginine ("Arg") residue instead of a proline ("Pro") residue. The present Sequence Listing provides the correct proline designation. No other changes to the previously submitted sequences have been made.

The present Office Action includes a complete listing, on five (5) text pages, of all 31 sequences in the Sequence Listing. These sequences, submitted herewith in both paper and computer readable form, correspond to the sequences described in Figures 15A and 15B of the application as filed and do not constitute new matter.

Statement Under 37 CFR § 1.821(f)


The content of the official Sequence Listing submitted herewith and the computer readable copy also submitted herewith are the same.

It is believed that the requirements identified in the *Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures* dated November 13, 2002 have been fully addressed in this response. However, if a telephone conference would facilitate the resolution of any issue, the Examiner is invited to telephone the undersigned at (713) 561-6374.

Respectfully submitted,

01/13/02

Date



Timothy L. Scott
Attorney for Assignee
Reg. No.: 37,931